Management and treatment of hepatitis C viral infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office

American Journal of Gastroenterology

Volumn 101, Issue 10, 2006, Pages 2360-2378

  Yee, Helen S ^a   Currie, Sue L ^b   Darling, Jama M ^b   Wright, Teresa L ^b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CONSENSUS INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; METHADONE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; THROMBOPOIETIN;

AFRICAN AMERICAN; ALCOHOLISM; ALOPECIA; AUTOIMMUNE DISEASE; BODY MASS; BONE MARROW SUPPRESSION; CANCER RISK; CYTOPENIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FATTY LIVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL SERVICE; MOOD DISORDER; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; STATISTICAL SIGNIFICANCE; SUBSTANCE ABUSE; SUPERINFECTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNITED STATES; VIRUS TITRATION;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION;

EID: 33749183244     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00754.x     Document Type: Review

References (84)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
2. Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 2005;41:88-96.
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
4. El-Serag HB. Hepatocellular carcinoma: An epidemiologic view. J Clin Gastroenterol 2002;35:S72-8.
5. CDC. Recommendations for prevention and control of hepatitis C virus HCV infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR 1998;47:1-39.
6. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002;36:S3-20.
7. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
8. Beck AT, Steer RA, Brown GK. Beck Depression Inventory manual. San Antonio, TX: Psychological Corporation, 1996.
9. The VA Hepatitis C Resource Center Program and National Hepatitis C Program Office VHA. Management of psychiatric and substance use disorders in patients with hepatitis C. A reference for hepatitis C care providers. 2005:1-36.
10. NIAAA. The physician's guide to helping patients with alcohol problems. Bethesda, MD: National Institutes of Health, 1995. NIH publication number 95-3769.
11. Rebetol®. Kenilworth, NJ: Schering Corporation, 2002.
12. Pegasys®. Nutley, NJ: Hoffman-La Roche Inc, 2005.
13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
14. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
15. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
16. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
17. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71.
18. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
19. Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kD) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004;39:1702-8.
20. Sanchez-Tapias J, Diago M, Enriquez J, et al. Longer treatment duration with peginterferon alfa-2a (40 kD) (Pegasys®) and ribavirin (Copegus®) in naïve patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: Final results of the randomized, multicenter Teravic-4 Study. Hepatology 2004;40:218A.
21. Berg T, von Wagner MHT, Buggisch P, et al for the German Study Group PEGASYS + COPEGUS in HCV Genotype 1. Reduction of the relative relapse rate by prolongation of the duration of a therapy with peginterferon alfa-2a plus ribavirin in patients with genotype 1 infection up to 72 weeks. Hepatology 2005;40:238A.
22. Jensen DM, Morgan T, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40kd)/ribavirin therapy. Hepatology 2006;43:454-60.
23. Ferenci P, Bergholz U, Laferl H, et al. Is shorter treatment with peginterferon alfa-2a (40 KD) (PEGASYS) plus ribavirin (COPEGUS) possible in HCV genotype 1 'super-responders'? Preliminary results of a prospective randomized clinical trial. Hepatology 2005;42:218A.
24. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
25. von Wagner M, Huber M, Berg T, et al. Peginterferon-alfa-2a (40 kD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
26. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.
27. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology 2004;40:1260-5.
28. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-72.
29. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
30. Afdahl N, Freilich B, Levine R, et al. Colchicine versus PEG-Intron Long Term (COPILOT) Trial: Interim analysis of clinical outcomes at year 2. Hepatology 2004;40:239A.
31. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23; discussion 947.
32. Jacobson IM, Gonzalez SA, Ahmed F, et al. A randomized trial of pegylated interferon alfa-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005;100:2453-62.
33. Poynard T, Schiff E, Terg R, et al. Sustained virologic response (SVR) in the EPIC3 trial:Week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving PegIntron/Rebetol (PR) weight based dosing (WBD). J Hepatol 2005;42:40.
34. Leevy CC, CBlatt LM. Predictive model and sustained virologic response for PEG IFN-alfa-2 + weight-based ribavirin nonresponders re-treated with IFN alfacon-1 + weightbased ribavirin. Gastroenterology 2005;128:A-715.
35. Grieve R, Roberts J, Wright M, et al. Cost-effectiveness of interferon {alfa} or peginterferon {alfa} with ribavirin for histologically mild chronic hepatitis C. Gut 2006 (epublication ahead of print).
36. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002;36:S179-84.
37. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kiloDaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-32.
38. Thakeb FIA, Oman MM, Awady MM, et al. Randomized controlled trial of peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus-genotype 4 among Egyptian patients. Hepatology 2003;38:738A.
39. Diago M, Hassanein T, Rodes J, et al. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alfa2a and ribavirin. Ann Intern Med 2004;140:72-3.
40. Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon {alfa}-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut 2005;54:858-66.
41. Mauss S, Berger F, Goelz J, et al. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004;40:120-4.
42. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug Alcohol Depend 2002;67:117-23.
43. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-46.
44. Loguercio C, Di Pierro M, Di Marino MP, et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: Prevalence and effect on clinical, virological and pathological aspects. Alcohol 2000;35:296-301.
45. Anand B, Currie S, Dieperink E, et al. Alcohol use and treatment of hepatitis C virus: Results of a national multicenter study. Gastroenterology 2006;130:1607-16.
46. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
47. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484-90.
48. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.
49. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004;292:2839-48.
50. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9.
51. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
52. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8.
53. Darbepoetin. Thousand Oaks, CA: Amgen Manufacturing, Limited, 2004.
54. Tien P, Wright T. Management and treatment of hepatitis C virus infection in HIV-infected adults: Recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol 2005;100:1-17.
55. Tokars JI, Miller ER, Alter MJ, et al. National surveillance of dialysis-associated diseases in the United States, 1997. Semin Dial 2000;13:75-85.
56. Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000;11:1896-902.
57. Russo MW, Goldsweig CD, Jacobson IM, et al. Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety. Am J Gastroenterol 2003;98:1610-5.
58. Lamb M, Marks I, Wynohradnyk L, et al. 40 kDa peginterferon alfa-2a (Pegasys) can be administered safely in patients with end-stage renal disease. Hepatology 2001;34:326A.
59. Russo M, Ghalib R, Sigal S, et al. A multi-center randomized trial of pegylated interferon alfa-2b monotherapy (Peg-Intron) in patients with chronic hepatitis C and end stage kidney disease on dialysis. Hepatology 2004;40:399A.
60. Peg-Intron®. Kenilworth, NJ: Schering Corporation, 2005.
61. Copegus®. Nutley, NJ: Roche Pharmaceuticals, 2005.
62. Jaeckel E, Markus C, Wedemeyer J, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-7.
63. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-8.
64. Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alfa-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005;42:329-33.
65. Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon alfa therapy in acute hepatitis C: Relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004;39:1721-31.
66. Rocca P, Bailly F, Chevallier M, et al. Early treatment of acute hepatitis C with interferon alfa-2b or interferon alfa-2b plus ribavirin: Study of sixteen patients. Gastroenterol Clin Biol 2003;27:294-9.
67. Everson GT, Forman J, Kugelmas L, et al. Treatment of advanced hepatitisCwith a lowaccelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-62.
68. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1-9.
69. Gopal DV, Rabkin JM, Berk BS, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001;7:181-90.
70. Dumortier J, Scoazec JY, Chevallier P, et al. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004;40:669-74.
71. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005;41:289-98.
72. Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004;78:1303-7.
73. Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004;10:859-67.
74. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
75. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11.
76. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004;40:1450-8.
77. Epoetin. Thousand Oaks, CA: Amgen Inc., 2005.
78. Procrit®. Raritan, NJ: Manufactured by Amgen Inc. and distributed by Ortho Biotech Products, L.P., 2005.
79. Ishizone S, Makuuchi M, Kawasaki S, et al. Effect of granulocyte colony-stimulating factor on neutropenia in liver transplant recipients with hypersplenism. J Pediatr Surg 1994;29:510-3.
80. Rolando N, Clapperton M, Wade J, et al. Administering granulocyte colony-stimulating factor to acute liver failure patients corrects neutrophil defects. Eur J Gastroenterol Hepatol 2000;12:1323-8.
81. Pardo M, Castillo I, Navas S, et al. Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alfa. J Med Virol 1995;45:439-44.
82. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-9.
83. Kawasaki T, Takeshita A, Souda K, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999;94:1918-22.
84. Rustgi VK, Lee P, Fennegan S, et al Safety and efficacy of recombinant human IL-11 (oprelvekin) in combination with interferon/ribavirin in hepatitis C patients with thrombocytopenia. Hepatology 2002;36:361A.